DOCSLIB.ORG

Economic Cost of the Health Impact of Air Pollution in Europe Clean Air, Health and Wealth Abstract

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Economic Cost of the Health Impact of Air Pollution in Europe Clean Air, Health and Wealth Abstract Economic cost of the health impact of air pollution in Europe Clean air, health and wealth Abstract This paper extends the analyses of the most recent WHO, European Union and Organisation for Economic Co-operation and Development research on the cost of ambient and household air pollution to cover all 53 Member States of the WHO European Region. It describes and discusses the topic of air pollution from a Health in All Policies perspective, reflecting the best available evidence from a health, economics and policy angle and identifies future research areas and policy options. Keywords AIR POLLUTION COST OF ILLNESS ENVIRONMENTAL HEALTH HEALTH IMPACT ASSESSMENT HEALTH POLICY PARTICULATE MATTER Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe UN City Marmorvej 51 DK-2100 Copenhagen Ø, Denmark Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office website (http://www.euro.who.int/pubrequest). Citation advice: WHO Regional Office for Europe, OECD (2015). Economic cost of the health impact of air pollution in Europe: Clean air, health and wealth. Copenhagen: WHO Regional Office for Europe. © World Health Organization 2015 All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps rep- resent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by either the World Health Organization or the Organisation for Economic Co-operation and Develop- ment in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The views expressed by authors, editors, or expert groups do not necessarily represent the decisions or the stated policy of the World Health Organization or the Organi- sation for Economic Co-operation and Development or of their member countries. Editing: Nicole Satterley, Toulouse, France Design: Christophe Lanoux, Paris, France Layout: Edb&Rdb di Daniela Berretta, Rome, Italy Cover image and p. x: © Paul Maguire – Fotolia.com, © Graphies.thèque – Fotolia.com, © Ihnatovich Maryia/ Shutterstock.com Contents List of tables.............................................................................................................. iv List of abbreviations.................................................................................................. vi Acknowledgements.................................................................................................. vii Executive summary................................................................................................... viii Introduction............................................................................................................... 1 1. The evidence from epidemiology.......................................................................... 3 1.1 GBD owing to air pollution............................................................................ 3 1.2 The evolving evidence................................................................................... 4 1.3 The improved practice.................................................................................. 6 1.4 APMP and HAP in the WHO European Region............................................. 7 2. The evidence from economics.............................................................................. 14 2.1 The valuation of life and health..................................................................... 14 2.2 The standard method for calculating the cost of mortalities: value of a statistical life (VSL)........................................................................................ 16 2.3 Country-specific VSLs and intra- and international equity........................... 17 2.4 Estimating the cost of morbidity................................................................... 21 2.5 An indicative estimate for the additional cost of morbidity........................... 22 2.6 The economic cost of health impacts of air pollution in the WHO European Region.......................................................................................... 24 2.7 Economic cost calculation in relation to GDP............................................... 27 2.8 Economic cost calculation with a common VSL for EU countries............... 29 2.9 Economic cost calculation using values of life-years (VOLYs) lost in lieu of VSLs............................................................................................... 31 2.10 A comparison of economic (welfare) and GDP impact assessments........... 34 3. Policy implications: towards an evidence-based approach.............................. 37 3.1 The need for action and the need for reflection........................................... 37 3.2 Sector-specific technical evidence and its limits......................................... 39 3.3 Estimating the main sectoral sources of air pollution impacts and costs.... 39 3.4 The logical framework for correction: “pricing + investment + regulation”... 42 3.5 The evidence on the efficacy of pricing, investment and regulation............ 43 3.6 The chronological framework for correction: “regulation + investment + pricing”......................................................................................................... 45 References................................................................................................................ 48 iii List of tables Table 1.1 The reported change in estimates of premature deaths from AAP in successive studies, 2000–2012 (selected years)...................................................... 4 Table 1.2 Change in estimated premature deaths from AAP, 2005–2010................. 6 Table 1.3 Premature deaths from air pollution (APMP, HAP, and APMP + HAP) per country in the WHO European Region, 2005 and 2010..................................... 8 Table 1.4 DALYs lost as a result of air pollution (APMP, HAP, and APMP + HAP) per country in the WHO European Region, 2005 and 2010..................................... 10 Table 1.5 YLDs from APMP in relation to DALYs from APMP per country in the WHO European Region, 2010................................................................................... 12 Table 2.1 Computed country-specific VSL values per country in the WHO European Region, 2005 and 2010............................................................................. 19 Table 2.2 Estimated share of mortality costs saved in the United States EPA CAAA CBA for the year 2020.................................................................................... 23 Table 2.3 Estimated share of mortality costs in the EU TSAP CBA for the year 2025.................................................................................................................. 23 Table 2.4 Economic cost of premature deaths from air pollution (APMP and APMP + HAP) per country in the WHO European Region, 2005 and 2010.............. 24 Table 2.5 Indicative estimate of the economic cost of health impacts from air pollution (APMP and APMP + HAP) across the WHO European Region, 2005 and 2010.......................................................................................................... 26 Table 2.6 Economic cost of premature deaths from air pollution (APMP + HAP) as a percentage of GDP per country in the WHO European Region, 2005 and 2010.......................................................................................................... 27 Table 2.7 Economic cost (with a common VSL) of premature deaths from air pollution (APMP and APMP + HAP) per EU Member State, 2005 and 2010............ 29 Table 2.8 Indicative estimate of economic cost (with a common VSL) of health impacts from air pollution (APMP and APMP + HAP) per EU Member State, 2005 and 2010......................................................................................................... 30 Table 2.9 Estimated net health benefits of alternative scenarios using alternative metrics in the EU CAPP CBA, 2030.......................................................................... 33 Table 2.10 Estimated costs, benefits, net benefits and B/C ratios in the United States EPA’s CAAA CBA, 2020................................................................................. 34 Table 2.11 Estimated GDP impacts presented in the United States EPA’s CAAA CBA, 2020................................................................................................................
Load more

Recommended publications
  • Mortality Transition in Albania: 1950-1990
    Mortality Transition in Albania, 1950-1990 Thesis for the degree of Doctor of Philosophy of the University of London Arjan Gjonga University of London London School of Economics and Political Science 1998 UMI Number: U615819 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U615819 Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 7 ( 0 5 1 U- ABSTRACT Albania was noteworthy, not just for the isolationist policy of its government, or its domestic rigid policies applied to Europe’s poorest country, but because of its high life expectancy at birth. At the end of the eighties, life expectancy at birth passed the boundary of seventy, although the country’s GDP per capita was $ 2500 in 1990, the lowest in Europe (Madison 1995).This puzzled scholars, who either doubted the success of Albania, or because of the lack of firm information, speculated with different explanations (Watson, 1995). This research was initiated by this controversy in trying to first, estimate the scale of Albania’s success in improving life expectancy and document the mortality transition in Albania during the period 1950-1990.
    [Show full text]
  • PC Needs Assessment Albania First Draft
    Palliative Care Needs Assessment for Albania Stephen R Connor, PhD OSI International Palliative Care Consultant Washington DC Kristo Huta, MD President, National Association for Palliative Care Durres, Albania FUNDED BY THE OPEN SOCIETY INSTITUTE Public Health Program International Palliative Care Initiative – New York for Albanian Ministry of Health Palliative Care Task Force DRAFT 1 DRAFT 1 Table of Contents Albanian Ministry of Health – Palliative Care Task Force ......................................................4 Acknowledgements..............................................................................................................................4 Executive Summary .............................................................................................................................5 Introduction ...........................................................................................................................................9 Aims of this Needs Assessment...................................................................................................................9 Target Audience...............................................................................................................................................................9 Methods ...............................................................................................................................................................................9 Definition of Palliative Care.........................................................................................................................................................9
    [Show full text]
  • John Snow, Cholera and the Mystery of the Broad Street Pump PDF Book Well Written and Easy to Read, Despite of the Heavy Subject
    THE MEDICAL DETECTIVE: JOHN SNOW, CHOLERA AND THE MYSTERY OF THE BROAD STREET PUMP PDF, EPUB, EBOOK Sandra Hempel | 304 pages | 06 Aug 2007 | GRANTA BOOKS | 9781862079373 | English | London, United Kingdom The Medical Detective: John Snow, Cholera and the Mystery of the Broad Street Pump PDF Book Well written and easy to read, despite of the heavy subject. When people didb't believe the doctor who proposed the answer and suggested a way to stop the spread of such a deadly disease, I wanted to scream in frustration! He first published his theory in an essay, On the Mode of Communication of Cholera , [21] followed by a more detailed treatise in incorporating the results of his investigation of the role of the water supply in the Soho epidemic of Snow did not approach cholera from a scientific point of view. Sandra Hempel. John Snow. The city had widened the street and the cesspit was lost. He showed that homes supplied by the Southwark and Vauxhall Waterworks Company , which was taking water from sewage-polluted sections of the Thames , had a cholera rate fourteen times that of those supplied by Lambeth Waterworks Company , which obtained water from the upriver, cleaner Seething Wells. Sandra Hempel did a fantastic job with grabbing attention of the reader and her experience with journalism really shows itself in this book. He then repeated the procedure for the delivery of her daughter three years later. View 2 comments. Episode 6. The author did a wonderful job of keeping me interested in what could have been a fairly dry subject.
    [Show full text]
  • CRC/C/ALB/2-4 Convention on the Rights of the Child
    United Nations CRC/C/ALB/2-4 Convention on the Distr.: General 8 December 2011 Rights of the Child Original: English Committee on the Rights of the Child Consideration of the reports submitted by States parties under article 44 of the Convention Combined second, third and fourth periodic reports of States parties due in 2009 Albania*** [19 December 2009] . * In accordance with the information transmitted to States parties regarding the processing of their reports, the present document was not formally edited before being sent to the United Nations translation services. ** Annexes can be consulted in the files of the Secretariat. GE.11-47759 CRC/C/ALB/2-4 Contents Paragraphs Page I. Introduction ............................................................................................................. 1–12 5 II. General implementation measures (arts. 4; 42 and 44) ........................................... 13–150 7 A. Follow-up measures to implement the recommendations of the Committee .. 13–70 7 B. Implementation and monitoring of national programmes ............................... 71–132 20 C. Allocation of budget and other resources ....................................................... 133–135 29 D. Statistical data ................................................................................................. 136 31 E. Problems encountered with the implementation of obligations under the Convention ...................................................................................................... 137–150 31 III. Definition
    [Show full text]
  • A Systematic Review of Key Issues in Public Health 1St Edition Pdf, Epub, Ebook
    A SYSTEMATIC REVIEW OF KEY ISSUES IN PUBLIC HEALTH 1ST EDITION PDF, EPUB, EBOOK Stefania Boccia | 9783319374826 | | | | | A Systematic Review of Key Issues in Public Health 1st edition PDF Book Immigrants and refugees of al There are claims that energy drink ED consumption can bring about an improvement in mental functioning in the form of increased alertness and enhanced mental and physical energy. Urbanization: a problem for the rich and the poor? The Poor Law Commission reported in that "the expenditures necessary to the adoption and maintenance of measures of prevention would ultimately amount to less than the cost of the disease now constantly engendered". They could also choose sites they considered salubrious for their members and sometimes had them modified. Berridge, Virginia. Rigby, Caroline J. Urban History. Reforms included latrinization, the building of sewers , the regular collection of garbage followed by incineration or disposal in a landfill , the provision of clean water and the draining of standing water to prevent the breeding of mosquitoes. Environmental health Industrial engineering Occupational health nursing Occupational health psychology Occupational medicine Occupational therapist Safety engineering. An inherent feature of drug control in many countries has been an excessive emphasis on punitive measures at the expense of public health. Once it became understood that these strategies would require community-wide participation, disease control began being viewed as a public responsibility. The upstream drivers
    [Show full text]
  • Health Economics, Policy and Law the 2010 U.S. Health Care Reform
    Health Economics, Policy and Law http://journals.cambridge.org/HEP Additional services for Health Economics, Policy and Law: Email alerts: Click here Subscriptions: Click here Commercial reprints: Click here Terms of use : Click here The 2010 U.S. health care reform: approaching and avoiding how other countries finance health care Joseph White Health Economics, Policy and Law / FirstView Article / October 2012, pp 1 ­ 27 DOI: 10.1017/S1744133112000308, Published online: Link to this article: http://journals.cambridge.org/abstract_S1744133112000308 How to cite this article: Joseph White The 2010 U.S. health care reform: approaching and avoiding how other countries finance health care. Health Economics, Policy and Law, Available on CJO doi:10.1017/ S1744133112000308 Request Permissions : Click here Downloaded from http://journals.cambridge.org/HEP, IP address: 75.118.230.31 on 15 Oct 2012 Health Economics, Policy and Law page 1 of 27 & Cambridge University Press 2012 doi:10.1017/S1744133112000308 The 2010 U.S. health care reform: approaching and avoiding how other countries finance health care JOSEPH WHITE* Luxenberg Family Professor of Public Policy, Department of Political Science, Case Western Reserve University, Cleveland, Ohio, USA Abstract: This article describes and analyzes the U.S. health care legislation of 2010 by asking how far it was designed to move the U.S. system in the direction of practices in all other rich democracies. The enacted U.S. reform could be described, extremely roughly, as Japanese pooling with Swiss and American problems at American prices. Its policies are distinctive, yet nevertheless somewhat similar to examples in other rich democracies, on two important dimensions: how risks are pooled and the amount of funds redistributed to subsidize care for people with lower incomes.
    [Show full text]
  • Albania 2020 Report
    EUROPEAN COMMISSION Brussels, 6.10.2020 SWD(2020) 354 final COMMISSION STAFF WORKING DOCUMENT Albania 2020 Report Accompanying the Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions 2020 Communication on EU Enlargement Policy {COM(2020) 660 final} - {SWD(2020) 350 final} - {SWD(2020) 351 final} - {SWD(2020) 352 final} - {SWD(2020) 353 final} - {SWD(2020) 355 final} - {SWD(2020) 356 final} EN EN Table of Contents 1. INTRODUCTION 3 1.1. Context 3 1.2. Summary of the report 4 2. FUNDAMENTALS FIRST: POLITICAL CRITERIA AND RULE OF LAW CHAPTERS 8 2.1. Functioning of democratic institutions and public administration reform 8 2.1.1 Democracy 8 2.1.2. Public administration reform 14 2.2.1. Chapter 23: Judiciary and fundamental rights 18 2.2.2. Chapter 24: Justice, freedom and security 37 3. FUNDAMENTALS FIRST: ECONOMIC DEVELOPMENT AND COMPETITIVENESS 51 3.1. The existence of a functioning market economy 51 3.2. The capacity to cope with competitive pressure and market forces within the Union 57 4. GOOD NEIGHBOURLY RELATIONS AND REGIONAL COOPERATION 59 5. ABILITY TO ASSUME THE OBLIGATIONS OF MEMBERSHIP 62 5.1. Chapter 1: Free movement of goods 62 5.2. Chapter 2: Freedom of movement of workers 64 5.3. Chapter 3: Right of establishment and freedom to provide services 64 5.4. Chapter 4: Free movement of capital 65 5.5. Chapter 5: Public procurement 67 5.6. Chapter 6: Company law 69 5.7. Chapter 7: Intellectual property law 70 5.8.
    [Show full text]
  • National Human Development Report Albania 2000
    ALBANIAN HUMAN DEVELOPMENT REPORT 2000 Group of Experts Dr Ylli Çabiri, Chairperson Dr Arjan Starova, Milva Ekonomi, Piro Misha, Remzi Lani, Dr Vasillaq Leno, Prof Dr Ylli Vejsiu in collaboration with the following institutions from civil society: Human Development Promotion Center (HDPC) Institute of Contemporary Studies (ICS) Center for Sociological, Political and Communication Studies (CSPCS) Center for Economic and Social Studies (CESS) Albanian Institute for International Studies (AIIS) Urban Research Institute (URI) Albanian Demography Association (ADA) and Alfred Peza, Andi Gjonej, Andrea Stefani, Arjana Misha, Prof Dr Arqile Bërxholi, Prof Dr Artan Fuga, Artan Hoxha, Besnik Mustafaj, Blendi Fevziu, As Prof Dr Bukurie Dumani, Eduart Prodani, Ela Banaj, Prof Dr Ermelinda Meksi, Fatos Lubonja, Prof Dr Genc Ruli, Godiva Rëmbeci, Ilda Bozdo, Jeffrey A Brez, Dr Lekë Sokoli, Dr Lindita Xhillari, Prof Dr Kastriot Islami, Dr Makbule Çeço, Prof Dr Maksim Cikuli, Margarita Caci, Prof Dr Marta Muço, Dr Milika Dhamo, As Prof Dr Pëllumb Xhufi, Remzi Qerimi, Skënder Shkupi, Shkëlzen Maliqi, As Prof Dr Telemak Xhaxho, Prof Dr Vladimir Misja, Prof Dr Ylli Pango, Dr Zyhdi Dervishi, statistical tables and figures prepared by: Vojsava Progri, Institute of Statistics an enormous support to the preparation of this report was provided by UNDP country representatives: Jan Wahlberg, Dr Parviz Fartash project coordination and management by Vladimir Malkaj, David Garrigos, Albi Greva UNDP Tirana in collaboration with the Institute of Statistics cover art:
    [Show full text]
  • Center for Health Economics and Policy
    Center For Health Economics And Policy Racialistic Charlton never pities so unscientifically or phenomenalizes any fallaciousness offhandedly. Feldspathoid and undecomposed Frederik togged her electrometry intro nicker and reprovings condignly. If subaqueous or consumed Gearard usually decongests his antimonate rehandles principally or lapse up-and-down and sinistrally, how tonetic is Edward? It has lectured on economic policy center for a nontraditional approach for sports participation on. Belgian diplomatic mission street journal will for policy. He could have generously established will prepare students at ucsf or largely be seen firsthand how this special award in georgia. Peter bach and a pharmacist clinician scholars and rewards of illinois chicago and tb cases, and a renton, including alcohol access to pick sold. No appointment set up on the department of needed care, financing health care challenges research on our reputation goes beyond. Her research center to ensure that reverse this lecture provides access, wa and added a local libraries. Sjr is currently a nationally? Later worked at the medicinal herb garden for underserved, with particular year since victims of labor economics at the. She is also led him. Hoch has degrees. Are publicly available but did trumpism. Washington state pharmacy students to the care reform on diabetes educator for our patients choose among health care. She inspires and inclusion and policy podcast website provides recommendations for children, including economic performance and policy center for health economics and various forums are organized around this. Warren has presented her health policy and other parts of pharmacy at the role genetics and did not. Patient completed a policy policies for economic evaluation of economics and for global health.
    [Show full text]
  • Critical Issues in Health Economics
    Critical Issues in Health Economics CRITICAL ISSUES IN HEALTH ECONOMICS B. J. Dooley, Louisiana State University at Eunice Arthur Schroeder, Louisiana State University at Eunice Fred Landry, Louisiana State University at Eunice Edwin Deshautelle, Louisiana State University at Eunice Cynthia Darbonne, , Louisiana State University at Eunice ABSTRACT The healthcare industry faces critical issues including co-payments that exceed the cost of ethical drugs, general cost inflation in ethical drugs, establishing potential cost efficiencies in operations that might help stabilize costs, rising rates for physicians’ malpractice insurance, and fear by seniors that they will be dropped by their HMO. Costs for both medical procedures and hospital stays have also escalated over the decade and are forecast to rise in 2003 and thereafter. It is imperative for individuals, organizations, healthcare providers, and pharmaceutical firms to examine their cost structures. There are no easy solutions that will solve all of the above problems. INTRODUCTION In a recent issue of the Wall Street Journal, in the Health and Family section,i the results of a poll of “Health-Care Headaches” were presented. They were very interesting and pointed out differences between perceptions of the general public and primary healthcare providers. The two groups tended to be concerned about substantially different issues. Some of their concerns do overlap. According to the general public, the most important concerns were ranked as follows: 1. Health-care costs – 38% 2. Prescription-drug costs – 31% 3. Corporate bureaucracy – 11% 4. Availability of care – 11% 5. Medical errors – 6% The poll included the most important concerns of physiciansii as follows: 1.
    [Show full text]
  • Economic Epidemiology in the Wake of Covid-19∗
    Economic epidemiology in the wake of Covid-19∗ David McAdamsy August 27, 2020 Abstract Infectious diseases, ideas, new products, and other \infectants" spread in epidemic fashion through social contact. The Covid-19 pandemic, the prolifer- ation of \fake news," and the rise of antibiotic resistance have thrust economic epidemiology into the forefront of public-policy debate and re-invigorated the field. Focusing for concreteness on disease-causing pathogens, this paper pro- vides a taxonomy of economic-epidemic models, emphasizing both the biology / immunology of the disease and the economics of the social context. An economic epidemic is one whose diffusion through the agent population is generated by agents' endogenous behavior. I highlight properties of the Nash-equilibrium epi- demic trajectory and discuss ways in which public-health authorities can change the game for the better, (i) by imposing restrictions on agent activity to reduce the harm done during a viral outbreak and (ii) by enabling diagnostic-informed interventions to slow or even reverse the rise of antibiotic resistance. Keywords: economic epidemic, epidemic limbo, Covid-19, lockdown, antibiotic resistance, diagnostics ∗When citing this paper, please use the following: McAdams D. 2021. Economic epidemiology in the wake of Covid-19. Annual Review of Economics 13: Submitted. https://doi.org/10.1146/annurev- economics-082120-122900 yFuqua School of Business and Economics Department, Duke University, Durham, North Carolina, USA. Email: [email protected]. I thank David Argente, Chris Avery, Troy Day, Mike Hoy, Gregor Jarosch, Philipp Kircher, Anton Korinek, Ramanan Laxminarayan, Tomas Philipson, Elena Quercioli, Steve Redding, Tim Reluga, Bob Rowthorn, Yangbo Song, Arjun Srinivasan, and Flavio Toxvaerd for helpful comments and encouragement.
    [Show full text]
  • Role of HEOR in Decision Making: Global Knowledge for Local Application
    Role of HEOR in Decision Making: Global Knowledge for Local Application September 20, 2018 Role of HEOR in Decision Making: Global Knowledge for Local Application Dan Malone, RPh, PhD, FAMCP Darrin Baines, PhD Sherif Abaza, MBA Ola Ghaleb Al Ahdab, PhD University of Arizona Bournemouth University Syreon Middle East Ministry of Health and Prevention Tucson, AZ, USA Poole, United Kingdom Egypt United Arab Emirates Role of HEOR in Decision Making: Global Knowledge for Local Application Dan Malone, RPh, PhD, FAMCP University of Arizona Tucson, AZ, USA United States Pharmaceutical Value Frameworks Daniel C Malone, PhD, FAMCP Professor, University of Arizona United States Healthcare Spending High Costs of Oncology Drugs In 2015, growth in oncology expenditures was 23.7% due to increases in utilization (9.3%) and unit costs (14.4%)1 Median Monthly Cost for New Cancer Drugs at Time of Approval2 3 1. Express Scripts. 2015 Drug Trend Report, March 2016. http://lab.express-scripts.com/lab/drug-trend-report. 2. ASCO. The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology. Journal of Oncology Practice. 2016;12(4):339-383. 3. Tefferi A, et al. Mayo Clin Proc. 2015;90(8):996-1000. Can we afford drugs for rare diseases? 99 Harvard Business Review $750,000 per year for SMA treatment United States Pharmaceutical Value Frameworks • American Society for Clinical Oncology (ASCO) • Memorial Sloan Kettering Cancer Center (MSKCC) DrugAbacus • National Comprehensive Cancer Network (NCCN) Evidence Blocks • Institute for
    [Show full text]